Cargando…

Impact of the Bim Deletion Polymorphism on Survival Among Patients With Completely Resected Non–Small-Cell Lung Carcinoma

PURPOSE: A deletion polymorphism of the Bim gene has been reported to be a prognostic factor for patients with non–small-cell lung cancer (NSCLC) treated with epidermal growth factor receptor-tyrosine kinase inhibitors in the Asian population. We investigated the impact of the Bim deletion polymorph...

Descripción completa

Detalles Bibliográficos
Autores principales: Atsumi, Jun, Shimizu, Kimihiro, Ohtaki, Yoichi, Kaira, Kyoichi, Kakegawa, Seiichi, Nagashima, Toshiteru, Enokida, Yasuaki, Nakazawa, Seshiru, Obayashi, Kai, Takase, Yoshiaki, Kawashima, Osamu, Kamiyoshihara, Mitsuhiro, Sugano, Masayuki, Ibe, Takashi, Igai, Hitoshi, Takeyoshi, Izumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497739/
https://www.ncbi.nlm.nih.gov/pubmed/28717678
http://dx.doi.org/10.1200/JGO.2015.000638
Descripción
Sumario:PURPOSE: A deletion polymorphism of the Bim gene has been reported to be a prognostic factor for patients with non–small-cell lung cancer (NSCLC) treated with epidermal growth factor receptor-tyrosine kinase inhibitors in the Asian population. We investigated the impact of the Bim deletion polymorphism on survival among patients with completely resected NSCLC. PATIENTS AND METHODS: The Bim polymorphism was detected by polymerase chain reaction analysis. We measured overall survival (OS) and recurrence-free survival rates in 411 patients and postrecurrence survival (PRS) in 94 patients who experienced recurrence and received additional anticancer therapy. RESULTS: The Bim deletion polymorphism was detected in 61 patients (14.8%). OS rates were significantly lower for patients with the Bim deletion polymorphism than for those with the wild-type sequence. On multivariable analysis, the Bim deletion polymorphism was identified as an independent prognostic factor for OS (hazard ratio, 1.98; 95% CI, 1.17 to 3.36; P = .011). Among the 94 patients who experienced recurrence and were treated with anticancer therapy, patients with the Bim deletion polymorphism showed significantly poorer PRS than those with the wild-type sequence (median, 9.8 months v 26.9 months, respectively; P < .001). Multivariable analysis revealed that the Bim deletion polymorphism was an independent predictor of PRS (hazard ratio, 3.36; 95% CI, 1.75 to 6.47; P < .001). This trend remained apparent in subgroup analyses stratified by EGFR status, histology, and therapeutic modality. CONCLUSION: The Bim deletion polymorphism is a novel indicator of shortened PRS among patients with recurrent NSCLC treated with anticancer therapy in the Asian population.